Serena Williams Returns as GLP-1 Debate Over Performance Enhancement Heats Up
Serena Williams returned to competition at Queen’s Club in doubles with Victoria Mboko, signaling a potential Wimbledon run, after revealing she used GLP-1 drugs like tirzepatide and semaglutide to manage weight. The drugs are being monitored by WADA for potential performance enhancement, not banned yet, fueling a broader debate on sport's spirit versus science and how to handle such weight-loss therapies in elite sport.